Determination of comparative minimum inhibitory concentration (MIC) of bacteriocins produced by enterococci for selected isolates of multi-antibiotic resistant Enterococcus spp.

Advanced Pharmaceutical Bulletin

Volumn 1, Issue 2, 2011, Pages 75-79

  Hassan, Maryam ^a,b   Javadzadeh, Yousef ^a   Lotfipour, Farzaneh ^a,c   Badomchi, Rajabali ^b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antibiotic resistant; Bacteriocin; Enterococci; MIC; Microtiter

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; BACTERIOCIN; CHLORAMPHENICOL; CIPROFLOXACIN; ERYTHROMYCIN; GENTAMICIN; STREPTOMYCIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFICACY; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; LISTERIA INNOCUA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

EID: 84875912229     PISSN: 22285881     EISSN: 22517308     Source Type: Journal    
DOI: 10.5681/apb.2011.011     Document Type: Article

References (43)

1. Franz CM, Muscholl-Silberhorn AB, Yousif NM, Vancanneyt M, Swings J, Holzapfel WH. Incidence of virulence factors and antibiotic resistance among Enterococci isolated from food. Appl Environ Microbiol 2001 Sep; 67:4385-4389.
2. Semedo T, Santos MA, Lopes MF, Figueiredo Marques JJ, BarretoCrespo MT, Tenreiro R. Virulence factors in food, clinical and reference Enterococci: A common trait in the genus. Syst Appl Microbiol 2003 Mar; 26:13-22.
3. Sood S, Malhotra M, Das BK, Kapril A. Enterococcal infections & antimicrobial resistance. Indian J Med Res 2008; 128:111-121.
4. Shea K, Hilburger E, Baroco A, Oldfield E. Successful treatment of vancomycin-resistant Enterococcus faecium pyelonephritis with daptomycin during pregnancy. Ann Pharmacother 2008 May; 42:722-725.
5. Bhat KG, Paul C, Ananthakrishna NC. Drug resistant enterococci in a south Indian hospital. Tropical doctor 1998; 28:106-107.
6. Poggio C, Colombo M, Scribante A, Sforza D, Bianchi S. In vitro antibacterial activity of different endodontic irrigants. Dent Traumatol 2011; 28(3):205-209.
7. Wang JL, Hsueh PR. Therapeutic options for infections due to vancomycin-resistant enterococci. Expert Opin Pharmacother 2009; 10:785-796.
8. Heintz BH, Halilovic J, Christensen CL. Vancomycin-resistant enterococcal urinary tract infections. Pharmacotherapy 2010; 30:1136-1149.
9. Kayser FH. Safety aspects of enterococci from the medical point of view. Int J Food Microbiol 2003; 88:255-262.
10. Foulquié Moreno MR, Sarantinopoulos P, Tsakalidou E, De Vuyst L. The role and application of enterococci in food and health. Int J Food Microbiol 2006; 106:1-24.
11. Kristich CJ, Little JL, Hall CL, Hoff JS. Reciprocal Regulation of Cephalosporin Resistance in Enterococcus faecalis. MBio 2011; 2:e00199-11.
12. Franz CM, Huch M, Abriouel H, Holzapfel W, Galvez A. Enterococci as probiotics and their implications in food safety. Int J Food Microbiol 2011 Dec 2; 151:125-140.
13. Klare I, Konstabel C, Badstubner D, Werner G, Witte W. Occurrence and spread of antibiotic resistances in Enterococcus faecium. Int J Food Microbiol 2003 Dec 1; 88:269-290.
14. Wendt C, Wiesenthal B, Dietz E, Ruden H. Survival of vancomycin-resistant and vancomycin-susceptible enterococci on dry surfaces. J Clin Microbiol 1998; 36:3734-3736.
15. Aneja RK, Varughese-Aneja R, Vetterly CG, Carcillo JA. Antibiotic therapy in neonatal and pediatric septic shock. Curr Infect Dis Rep 2011; 13:433-441.
16. Linden PK. Optimizing therapy for vancomycin-resistant enterococci (VRE). Semin Respir Crit Care Med 2007; 28:632-645.
17. Bassetti M, Ginocchio F, Mikulska M, Taramasso L, Giacobbe DR. Will new antimicrobials overcome resistance among Gram-negatives. Expert Rev Anti Infect Ther 2011; 9:909-922.
18. Coates AR, Halls G, Hu Y. Novel classes of antibiotics or more of the same. Br J Pharmacol 2011; 163:184-194.
19. Butler MS, Cooper MA. Antibiotics in the clinical pipeline in 2011. J Antibiot (Tokyo) 2011; 64:413-425.
20. Wiesner J, Vilcinskas A. Antimicrobial peptides: the ancient arm of the human immune system. Virulence 2010; 1:440-464.
21. Guani-Guerra E, Santos-Mendoza T, Lugo-Reyes SO, Teran LM. Antimicrobial peptides: general overview and clinical implications in human health and disease. Clin Immunol 2010; 135:1-11.
22. Wimley WC, Hristova K. Antimicrobial peptides: successes, challenges and unanswered questions. J Membr Biol 2011 Jan; 239(1-2):27-34.
23. Venema K, Venema G, Kok J. Lactococcalbacteriocins: mode of action and immunity. Trends Microbiol 1995; 3:299-304.
24. Foulquié Moreno MR, Callewaert R, Devreese B, Van Beeumen J, De Vuyst L. Isolation and biochemical characterisation of enterocins produced by enterococci from different sources. J Appl Microbiol 2003; 94:214-229.
25. NCCLS. Performance standards for antimicrobial disk susceptibility tests. NCCLS document M2-A8 Approved standard. 8th ed. PA: NCCLS; 2003.
26. Fimland G, Johnsen L, Axelsson L, Brurberg MB, Nes IF, Eijsink VG, et al. A C-terminal disulfide bridge in pediocin-like bacteriocins renders bacteriocin activity less temperature dependent and is a major determinant of the antimicrobial spectrum. J Bacteriol 2000; 182:2643-2648.
27. Castro I, Bergeron MG, Chamberland S. Characterization of multiresistant strains of Neisseria gonorrhoeae isolated in Nicaragua. Sex Transm Dis 1993; 20:314-320.
28. Davies J. Bacteria on the rampage. Nature 1996; 383:219-220.
29. Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988; 319:157-161.
30. Mota-Meira M, Lapointe G, Lacroix C, Lavoie MC. MICs of mutacin B-Ny266, nisin A, vancomycin, and oxacillin against bacterial pathogens. Antimicrob Agents Chemother 2000; 44:24-29.
31. Piper C, Draper LA, Cotter PD, Ross RP, Hill C. A comparison of the activities of lacticin 3147 and nisin against drug-resistant Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother 2009; 64:546-551.
32. Moore JE, Barton MD, Blair IS, Corcoran D, Dooley JS, Fanning S, et al. The epidemiology of antibiotic resistance in Campylobacter. Microbes Infect 2006; 8:1955-1966.
33. Smith JL, Fratamico PM. Fluoroquinolone resistance in campylobacter. J Food Prot 2010; 73:1141-1152.
34. Hancock RE. Peptide antibiotics. Lancet 1997; 349:418-422.
35. Vaara M. New approaches in peptide antibiotics. Curr Opin Pharmacol 2009; 9:571-576.
36. Nusslein K, Arnt L, Rennie J, Owens C, Tew GN. Broad-spectrum antibacterial activity by a novel abiogenic peptide mimic. Microbiology 2006; 152:1913-1918.
37. Lohner K. New strategies for novel antibiotics: peptides targeting bacterial cell membranes. Gen Physiol Biophys 2009; 28:105-116.
38. Drider D, Rebuffat S. Prokaryotic Antimicrobial Peptides: From Genes to Applications. 1st ed. New York: Springer; 2011.
39. Park SC, Park Y, Hahm KS. The role of antimicrobial peptides in preventing multidrug-resistant bacterial infections and biofilm formation. Int J Mol Sci 2011; 12:5971-5992.
40. Peters BM, Shirtliff ME, Jabra-Rizk MA. Antimicrobial Peptides: Primeval Molecules or Future Drugs. PLoS Pathog 2010; 6:e1001067.
41. De Vuyst L, Foulquié Moreno MR, Revets H. Screening for enterocins and detection of hemolysin and vancomycin resistance in enterococci of different origins. Int J Food Microbiol 2003; 84:299-318.
42. Giraffa G. Functionality of enterococci in dairy products. Int J Food Microbiol 2003; 88::215-222.
43. Suppola JP, Kolho E, Salmenlinna S, Tarkka E, Vuopio-Varkila J, Vaara M. vanA and vanB incorporate into an endemic ampicillin-resistant vancomycin-sensitive Enterococcus faecium strain: effect on interpretation of clonality. J Clin Microbiol 1999; 37:3934-3939.